Navigation Links
ERT Launches New Website to Support Significant Commercial Growth
Date:2/15/2012

PHILADELPHIA, Feb. 15, 2012 /PRNewswire/ -- ERT (NASDAQ: ERT), a global technology-driven provider of health outcomes services and customizable medical devices to biopharmaceutical sponsors and Contract Research Organizations (CROs), announced today the launch of a new corporate website to further elevate its market and thought leadership position. Complementing the company's commercial growth in the last 18 months, web traffic to ERT's website increased by 41% from June 2010 to October 2011, as visitors sought further detailed information about ERT's comprehensive range of Cardiac Safety, Respiratory and ePRO solutions. To access the new website, visit www.ert.com.

The newly created website has been designed to reflect ERT's position as a company offering unrivaled processes and scientific expertise to collect, analyze and report on clinical data. This is done in order to support the determination of health outcomes critical to the approval, labeling and reimbursement of pharmaceutical products.

Created to provide a new online customer experience, the website provides enhanced content and improved navigation in order to give visitors a more comprehensive and in-depth understanding of ERT's services and expertise in the health outcomes research field. Providing in-depth information on ERT's distinctive cardiac safety, respiratory and ePRO solutions, visitors are also able to learn about ERT's clinical consulting services, which offer essential scientific and regulatory expertise in order to ensure quality trial data.

ERT's commitment to making valuable resources available to patients and clients is fully realized by the new website. Leveraging the research of ERT's experts and other thought leaders, the site offers a resource center that provides continually updated links to articles, white papers and webinars, in addition to up-to-date news stories. Featuring images and quotes from both junior and senior staff throughout the website, the new aesthetic enables users to see the human side of ERT and familiarize themselves with the experts and dedicated staff that support their research every day.

John Blakeley, Chief Commercial Officer, comments: "Our traditional markets are changing and we felt strongly that a new online presence was needed to better support our Sponsors and our CRO partners. This new site provides a valuable resource center that allows relevant stakeholders to access industry specific information and case studies."

For further information on ERT and its technology and services, please email info@ERT.com, call +1 215 972 0420 or visit www.ert.com.

For further press information, please contact John Blakeley, ERT, +1 215 972 0420, jblakeley@ert.com 

About ERT

ERT (www.ert.com) is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and Contract Research Organizations (CROs) to achieve their drug development and healthcare objectives. ERT harnesses leading technology coupled with unrivaled processes and scientific expertise to collect, analyze, and report on clinical data to support the determination of health outcomes critical to the approval, labeling and reimbursement of pharmaceutical products. ERT is the acknowledged industry leader in centralized cardiac safety and respiratory efficacy services and also provides electronic Patient Reported Outcomes (ePRO) and Outcomes Assessments for multiple modalities across all phases.


'/>"/>
SOURCE ERT
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Hooper Holmes Heritage Labs Division Launches New Home Diabetes Test
2. ICON Medical Imaging Launches New Service to Boost Reliability of Cardiology Studies
3. StollerUSA Launches Bio-Forge.com to Offer Solutions for Crops Under Stress
4. GEECF: Spectrum Launches Zero Waste Philippines and Gears Towards Cheap Green Energy
5. ETEX Launches Innovative Osteoinductive Orthobiologic, EquivaBone(TM)
6. ChemAxon Launches Marvin and JChem Version 5.1; Name to Structure Generation, OLE 2 and JavaScript Integration
7. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
8. Peakdale Molecular Launches AssayReady4U(TM) in Collaboration With ChemPrintCo LLC
9. BIOLOCK(TM) USA Launches Affordable Fingerprint door Locks for Homes and Offices
10. SearchMedica Launches Practice Management Search Engine for Medical Professionals
11. Familybuilder Launches the Familybuilder Global Network at DEMOfall 08
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM ... firm for the life sciences and healthcare industries, announces a presentation by Subbu ... , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a ...
Breaking Biology Technology:
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):